Not Yet Recruiting NA INTERVENTIONAL 2-arm
NCT07350824
Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in Hepatocellular Carcinoma: A Prospective, Multicenter Study
Sponsor: Tongji Hospital
Conditions
HCC Minimal Residual Disease Recurrence
Interventions
Active monitoring Adjuvant PD-1 inhibitors
Updated 1 time since 2026 Last updated: Jan 9, 2026 Started: Dec 31, 2025 Primary completion: Dec 31, 2027 Completion: Dec 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07350824, this NA trial focuses on HCC and Minimal Residual Disease and remains actively recruiting participants. Sponsored by Tongji Hospital, it has been updated 1 time since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Not Yet Recruiting — NA
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Tongji Hospital
Data source: Tongji Hospital
For direct contact, visit the study record on ClinicalTrials.gov .